User: Guest  Login
Title:

[Indications for pre- and postoperative treatment with imatinib for gastrointestinal stromal tumors]

Document type:
English Abstract; Journal Article; Review
Author(s):
Heger, U; Weitz, J; Lordick, F
Abstract:
Imatinib is a tyrosine kinase inhibitor directed against the KIT and the PDGF-alpha receptors. Imatinib has proven efficacy in the treatment of metastatic GIST with a response rate achieving 70%, but treatment with imatinib alone is not curative. The median progression-free survival is about 2 years. In locally advanced GIST, primary treatment with imatinib proved to be safe and feasible in several cohort studies. The goal of any curatively intended surgical treatment for GIST is R0 resection. T...     »
Journal title abbreviation:
Chirurg
Year:
2008
Journal volume:
79
Journal issue:
7
Pages contribution:
630-7
Language:
de
Fulltext / DOI:
doi:10.1007/s00104-008-1526-6
Pubmed ID:
http://view.ncbi.nlm.nih.gov/pubmed/18548219
Print-ISSN:
0009-4722
TUM Institution:
III. Medizinische Klinik und Poliklinik (Hämatologie / Onkologie)
 BibTeX